Cargando…
Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2(+/−) Mice Is Superior to Everolimus Alone()
Tuberous sclerosis (TSC) is an inherited tumor syndrome caused by mutations in TSC1 or TSC2 that lead to aberrant activation of mTOR and development of tumors in multiple organs including the kidneys. The mTOR inhibitors rapamycin and everolimus (rapalogs) have demonstrated clinical efficacy in trea...
Autores principales: | Yang, Jian, Samsel, Paulina A., Narov, Kalin, Jones, Ashley, Gallacher, Daniel, Gallacher, John, Sampson, Julian R., Shen, Ming Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5238457/ https://www.ncbi.nlm.nih.gov/pubmed/28092822 http://dx.doi.org/10.1016/j.neo.2016.12.008 |
Ejemplares similares
-
The dual PI3K/mTOR inhibitor GSK2126458 is effective for treating solid renal tumours in Tsc2(+/-) mice through suppression of cell proliferation and induction of apoptosis
por: Narov, Kalin, et al.
Publicado: (2017) -
Assessment of Response of Kidney Tumors to Rapamycin and Atorvastatin in Tsc1(+/−) Mice
por: Shen, Ming Hong, et al.
Publicado: (2017) -
Efficacy of Dual Inhibition of Glycolysis and Glutaminolysis for Therapy of Renal Lesions in Tsc2(+/−) Mice()
por: Jones, Ashley T., et al.
Publicado: (2019) -
Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2
por: Kwiatkowski, David J, et al.
Publicado: (2015) -
Allosteric and ATP-Competitive Inhibitors of mTOR Effectively Suppress Tumor Progression-Associated Epithelial-Mesenchymal Transition in the Kidneys of Tsc2(+/−) Mice
por: Jones, Ashley T., et al.
Publicado: (2019)